Trials of the Corona vaccine are happening worldwide, but so far no effective vaccine has been prepared for children. Now a Chinese company Sinovac has claimed that its corona vaccine is safe for children between 3 and 17 years old. The company has made this claim based on preliminary data and has submitted this data to the Chinese Drug Regulators.
So far, more than 70 million shots of the Synovac vaccine have been delivered worldwide, including in China. China has approved the introduction of shots of this vaccine to adults but has not yet been approved for use on children as their immune system reacts differently to the vaccine. Only two of the children involved in the test had a high fever and the remaining children showed mild symptoms.
Two children with high fever and other mild symptoms
Synovac’s medical director Gang Jeng said that in the initial and middle-level clinical trials on more than 550 children, it was found that it was boosting immunity. According to the information given by Zeng, two children had a high fever after taking the vaccine dose. One child was 3 years old and the other child was 6 years old. The remaining children showed mild symptoms.
In such a situation, Professor Ing Ayeong Oye of Duke NUS Medical School, Singapore, says that according to this test the vaccine is safe and is increasing immunity to corona. Oi is playing his role in making another corona vaccine. However, he says that nothing can be said clearly from the data presented by the company in public.
Other vaccine companies are also doing trial
There have been very few cases of children getting corona infected, but to end the corona epidemic completely, they also need to give it a dose. The Pfizer vaccine has received clearance to apply to people over the age of 16 and is now being tested on people aged 12-16. Moderna is testing its vaccine on children over the age of 12 and last week the company announced to start a study on children under 12 years of age.
Government company Sinoform is preparing two vaccines and is studying the effectiveness of their vaccine on children. Sinoform submitted clinical data to regulators in January 2021, but it is not yet clear whether this data was submitted for one vaccine or for both vaccines.